Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
The September 14 workshop brought together multidisciplinary experts in extracellular vesicles – cell-secreted nanoparticles that mediate cell-cell communication.
Researchers at the National Eye Institute have mapped the 3D organization of genetic material of key developmental stages of human retinal formation, using intricate models of a retina grown in the lab.
This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD).
The National Eye Institute (NEI) has chosen Richard Lee, M.D., Ph.D., as the institute’s clinical director, overseeing clinical research and serving as clinical policy advisor for NEI.
Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma.
A longstanding member of the NEI/NIH community, Emily Chew, M.D., has been promoted to the title of NIH Distinguished Investigator for her tireless and prolific work as a care provider and clinical trialist.